Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) announces the completion of ezutromid dosing in patients with Duchenne muscular dystrophy (‘DMD’) for the full 48-week PhaseOut DMD clinical trial. Top-line data from the full trial continue to be expected in the third quarter of 2018.

As quoted in the press release:

“We believe the early improvements seen in muscle health in the interim data from PhaseOut DMD indicate ezutromid is reducing DMD disease severity. In the full trial results, we aim to see continued utrophin modulation and sustained changes in magnetic resonance parameters,”said Dr David Roblin, Chief Medical Officer and President of R&D of Summit. “These results, if positive, could form the basis of a regulatory filing of ezutromid, bringing this universal treatment to patients more rapidly.”

PhaseOut DMD is a Phase 2 open-label, multi-centre trial of the Company’s utrophin modulator, ezutromid, in patients with DMD. Previously announced 24-week interim data from PhaseOut DMD showed evidence of activity across three different measures. Specifically, ezutromid:

• Maintained the production of utrophin, a naturally occurring protein that can potentially substitute for dystrophin, as measured by muscle biopsy;
• Significantly and meaningfully reduced muscle damage, as measured by muscle biopsy; and
• Significantly reduced muscle inflammation, as measured by magnetic resonance.

Click here to read the full press release.